<code id='66849EE0BE'></code><style id='66849EE0BE'></style>
      • <acronym id='66849EE0BE'></acronym>
      <center id='66849EE0BE'><center id='66849EE0BE'><tfoot id='66849EE0BE'></tfoot></center><abbr id='66849EE0BE'><dir id='66849EE0BE'><tfoot id='66849EE0BE'></tfoot><noframes id='66849EE0BE'>
      • <optgroup id='66849EE0BE'><strike id='66849EE0BE'><sup id='66849EE0BE'></sup></strike><code id='66849EE0BE'></code></optgroup>
        5. <b id='66849EE0BE'><label id='66849EE0BE'><select id='66849EE0BE'><dt id='66849EE0BE'><span id='66849EE0BE'></span></dt></select></label></b><u id='66849EE0BE'></u>
          <i id='66849EE0BE'><strike id='66849EE0BE'><tt id='66849EE0BE'><pre id='66849EE0BE'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-09-07 08:38:39 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      Page View：9563
                                  
                                    
          
                                   
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP
          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
          advertisement
          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Medicare Advantage beneficiaries sue Humana over algorithm use
                                
                            
          Next article：  
                                      
                                          Duchenne breakthrough therapy leaves behind pioneering families
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles